G-protein β3 Subunit Gene 825C T Polymorphism and its Association with the Presence Severity and Duration of Vasculogenic Erectile Dysfunction

The CT genotype of GNB3 gene was more prevalent in patients with erectile dysfunction. The interaction between the T allele and erectile dysfunction was significant (P¼.004).

Mohammad Reza Safarinejad, M.D., Shiva Safarinejad, M.S., Nayyer Shafiei, B.Ch.E., Saba Safarinejad, S.B.

Volume 99, Issue 1, Pages 69-75.e5, January 2013


To investigate the association between G-protein β3 (GNB3) subunit gene 825C/T polymorphism and vasculogenic ED (VED).

Case-control study.

Private urology and andrology clinic.

The study included 246 patients with VED and 492 healthy controls, Caucasians of Iranian descent.

Typing of the polymorphism was performed using the polymerase chain reaction restriction fragment length polymorphism technique.

Main Outcome Measure(s):
To test the hypothesis of whether the presence of the 825T allele of the GNB3 gene is associated with an increased risk of VED.

The CT genotype was more prevalent in VED patients relative to healthy controls (adjusted odds ratio [OR] = 2.34; 95% confidence interval [CI], 1.10–4.26). Interaction between T allele carriership and VED was significant. The dominant model CT + TT variant was associated with a 3.74-fold increase in the adjusted risk (OR = 3.74; 95% CI, 1.11–12.4) for the occurrence of VED. Our results indicate that the GNB3 polymorphism is associated with higher systolic blood pressure, higher dyslipidemia, and higher body mass index. The 825TT genotype was associated with a more than five-fold increased risk of severe VED compared with the 825CC genotype (OR = 5.62; 95% CI, 3.54–9.25). Significantly different onset of age of VED was not found between the genotypes for the GNB3 polymorphism.

The GNB3 polymorphism is an independent risk factor for VED in Iranian males. Our findings confirm a role of GNB3 in the genetic susceptibility of VED and suggest that GNB3 polymorphism should be taken into consideration to improve the assessment of an individual’s risk of VED.

  • Carlos Balmori

    Congratulations for your paper. There are many questions to
    be resolved about the causes of VED. Response to phosphodiesterase inhibitors (PDEI5)
    in patients with genotype TT seems to demostrate its relationship with the
    nitric oxide pathway. However higher levels of systolic blood pressure and cholesterol in
    patients with TT genotype in the cases group and not this way in the control group should
    make us think about possible epigenetic factors that should be studied

    • Mohammad Reza Safarinejad

      Thank you for your scientific comment. I agree with you.

Translate »